For reprint rights or to purchase a copy of your Daily Journal photo, email Jeremy_Ellis@dailyjournal.com for prices or call 213-229-5424.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Perspective

Feb. 20, 2013

An open-source approach to cancer

The latest victory in the Myriad Genetics case in Australia, allowing Myriad Genetics to patent isolated DNA, has sparked new debate over the development of new drugs to treat cancer. By Kenneth Eade


By Kenneth Eade


The latest victory in the Myriad Genetics case in Australia, allowing Myriad Genetics to patent isolated DNA, has sparked new debate over the development of new drugs to treat cancer. At the forefront of a grass roots movement in this debate is Viratech.org, run by a subsidiary of Viratech Corp., which claims to be the first open-source biotech research and development platform, and brings to the biotech industry what the software industry ...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.